This article is part of a Chronicle. See more from this Chronicle

Eleventh Circuit Rejects the Strength of a Patent as a Criterion for the Legality of Reverse-Payment Settlements

William Rooney, Jodi Lucena-Pichardo, Jun 27, 2012

The Eleventh Circuit's recent decision in Federal Trade Commission v. Watson Pharmaceuticals, Inc. (the "AndroGel" decision) addresses the latest challenge to reverse-payment settlements. The Eleventh Circuit rejected the Federal Trade Commission's position that the lawfulness of a reverse-payment settlement depends on the perceived strength or weakness of the patent and concluded that a patent, unless previously invalidated, should be given its full exclusionary scope.

 

Links to Full Content

Comments

You can't post comments until you have logged in. Please login here or register.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments